Search Results for "Alks 5461 How To Get In Clinical Trial"
Original Source: A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
Matching Channels
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
Clinical Approvals - news, views, reports and blogs
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and eff...
Research has not found any adverse effects from consuming vitamin E in food. However, high doses of alpha-tocopherol supplements can cause hemorrhage and interrupt blood coagulation in animals, and...
Contract Research Organization news
A contract research organization, also called a clinical research organization, (CRO) is a service organization that provides support to the pharmaceutical and biotechnology industries in the form o...
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...
Matching News
Alkermes gains on Phase II MDD data
Alkermes plc (NASDAQ:ALKS) gained $4.12 (16%) to $29.72 on Wednesday after reporting that once-daily oral ALKS 5461 as adjunctive treatment met the primary endpoint in a Phase II trial to treat refrac...
Alkermes boosted by positive Ph II data on ALKS 5461 for major depressive disorder
Ireland-headquartered Alkermes (Nasdaq: ALKS) saw its shares rise 16% to $29.72, after it announced positive preliminary top-line results from a Phase II study of ALKS 5461, its novel drug compound fo...
Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder
Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an...
Alkermes Reveals Positive Results From ALKS 5461 Phase 2 Study For MDD
WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) Wednesday revealed positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder or MDD i...
Positive results from Alkermes’ ALKS 5461 phase 1/2 study on MDD
Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard t...
Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug ...
Three Cheers for Alkermes Running a Depression Study in the U.S. of A.
DUBLIN (TheStreet) -- First thing I did after reading Alkermes' announcement about positive results from a mid-stage study of its depression drug ALKS 5461 was to make sure the company didn't enroll...
Matching PubMed Articles
OBJECTIVE: To assess preliminarily the effectiveness of a novel opioid antagonist, ALKS-33, in binge eating disorder (BED). METHOD: In this randomized, placebo-controlled, flexible dose, proof-of-conc...
Opioid modulators for alcohol dependence.
Introduction: Studies have shown that opioid antagonists like naltrexone are efficient in reducing heavy drinking. The neurobiological mechanism by which opioid modulators affect drinking behavior is...
Do messages of scarcity increase trial recruitment?
INTRODUCTION: Psychological theory suggests that participants may be more likely to volunteer to join a clinical trial if they perceive places in the trial are a scarce commodity. MATERIAL AND METHODS...
Identifying patient information needs about cancer clinical trials using a Question Prompt List.
OBJECTIVE: Question Prompt Lists (QPLs) have demonstrated significant promise in facilitating communication in general, surgical and palliative oncology settings yet have not been tested in the oncolo...
When designing a clinical trial there is a need to design a study that achieves the objectives of a trial both efficiently and with minimum resources. This paper describes seven trial designs that cou...
